Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,649 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Accepts healthy volunteers

The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain

NCT02281162
Conditions
Schizophrenia, Metabolic Syndrome, Vitamin D Deficiency
Interventions
Blood Draw
Other
Lead sponsor
Creighton University
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Not applicable Interventional Results available

Aerobic Exercise for Cognition in Schizophrenia

NCT02621983
Conditions
Schizophrenia
Interventions
Aerobic Exercise, Balance and Stretching
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia

NCT01339858
Conditions
Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
Interventions
N-Acetyl Cysteine, sugar pill
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana
Conditions
Schizophrenia, Acute Episode
Interventions
Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Completed Not applicable Interventional Results available

Reproductive Life Planning for Women With Mental Illness

NCT03969589
Conditions
Psychotic Disorders, Mood Disorders, Stress Disorders, Post-Traumatic
Interventions
Reproductive Life Planning-Mental Health (RLP-MH) Intervention, Written Materials on Reproductive Life Planning
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Perry Point, Maryland
Conditions
Schizophrenia, First Episode Psychosis
Interventions
search engine advertisement campaign
Behavioral
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Glen Oaks, New York • Queens, New York
Conditions
Schizophrenia, PreDiabetes
Interventions
Bromocriptine
Drug
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Psychoses, Substance-Induced
Interventions
Ketamine, Dexmedetomidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Schizophrenia, Cognition Disorders
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • Piscataway, New Jersey + 1 more
Completed Not applicable Interventional Results available

Remediation of Auditory Recognition in Schizophrenia With tDCS

NCT02869334
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Active Transcranial direct current stimulation (tDCS), Sham Transcranial direct current stimulation (tDCS), Auditory Remediation, Control computer activities
Device · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integrated Care (IC) Models for Patient-Centered Outcomes

NCT03451630
Conditions
Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions
High-Touch, High-Tech, Optimal Discharge Planning
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Bellflower, California • Costa Mesa, California • Long Beach, California + 17 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Cannabinoid Response

NCT00678730
Conditions
COMT Gene Polymorphism
Interventions
delta 9 tetrahydrocannabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Schizophrenia, Cognition
Interventions
Sertindole, Quetiapine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
26
States / cities
Garden Grove, California • National City, California • Pasadena, California + 23 more
Conditions
Schizophrenia
Interventions
multifamily group-adherence, multifamily group-standard
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Granada Hills, California
Conditions
Schizophrenia
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 17 more
Completed Phase 2 Interventional Results available

A Multicenter Study of NAP (AL-108) in Schizophrenia

NCT00505765
Conditions
Schizophrenia
Interventions
AL-108, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more
Conditions
Alzheimer Disease, Psychosis
Interventions
KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Gilbert, Arizona • Chino, California • Naples, Florida + 2 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Schizophrenia
Interventions
Talnetant, placebo, risperidone
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
22
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 18 more
Conditions
Cognitive Impairment Associated With Schizophrenia (CIAS)
Interventions
KYN-5356 low dose, Placebo, KYN-5356 Medium Dose, KYN-5356 High Dose
Drug · Other
Lead sponsor
Kynexis B.V.
Industry
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
15
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 12 more
Conditions
Auditory Hallucinations, Schizophrenia
Interventions
Active tDCS, Sham tDCS
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects

NCT01600885
Conditions
NMDA Receptor Function
Interventions
Guanfacine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut
Conditions
Schizophenia Disorder, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 52 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
San Antonio, Texas